| local tumor necrosis factor-α inhibition in inflammatory bowel disease B Gareb, AT Otten, HW Frijlink, G Dijkstra, JGW Kosterink Pharmaceutics 12 (6), 539, 2020 | 71 | 2020 |
| Vitamin C supplementation in healthy individuals leads to shifts of bacterial populations in the gut—a pilot study AT Otten, AR Bourgonje, V Peters, BZ Alizadeh, G Dijkstra, HJM Harmsen Antioxidants 10 (8), 1278, 2021 | 50 | 2021 |
| The revised Atlanta criteria more accurately reflect severity of post-ERCP pancreatitis compared to the consensus criteria XJNM Smeets, N Bouhouch, J Buxbaum, H Zhang, J Cho, RC Verdonk, ... United European gastroenterology journal 7 (4), 557-564, 2019 | 37 | 2019 |
| Serological biomarkers of type I, III and IV collagen turnover are associated with the presence and future progression of stricturing and penetrating Crohnʼs disease AR Bourgonje, MS Alexdottir, AT Otten, R Loveikyte, AC Bay‐Jensen, ... Alimentary Pharmacology & Therapeutics 56 (4), 675-693, 2022 | 16 | 2022 |
| The effect of riboflavin supplementation on the systemic redox status in healthy volunteers: a post-hoc analysis of the RIBOGUT trial AR Bourgonje, AT Otten, MS Sadabad, JZH von Martels, MLC Bulthuis, ... Free Radical Biology and Medicine 190, 169-178, 2022 | 14 | 2022 |
| Infliximab formulation strategy for a stable ileo-colonic targeted oral dosage form intended for the topical treatment of inflammatory bowel disease B Gareb, M Beugeling, S Posthumus, AT Otten, G Dijkstra, JGW Kosterink, ... Journal of Drug Delivery Science and Technology 64, 102552, 2021 | 5 | 2021 |
| Effects of ileocolonic delivered vitamin B2, B3 and C (ColoVit) or the Groningen anti-inflammatory diet on disease course and microbiome of patients with Crohn’s disease (VITA … AT Otten, V Peters, I Barth, CL Stevens, AR Bourgonje, HW Frijlink, ... BMJ open 13 (3), e069654, 2023 | 4 | 2023 |
| Clinical validation of a capillary blood home-based self-sampling technique for monitoring of infliximab, vedolizumab, and C-reactive protein concentrations in patients with … AT Otten, HH van der Meulen, M Steenhuis, FC Loeff, DJ Touw, ... Inflammatory Bowel Diseases 30 (3), 325-335, 2024 | 2 | 2024 |
| Interleukin-18 inhibition in inflammatory bowel disease: a delicate balance S Geertsema, RR Fagundes, AT Otten, G Dijkstra, KN Faber, ... Inflammatory Bowel Diseases 30 (4), 693-694, 2024 | 1 | 2024 |
| The Risk of Developing Long COVID in Patients With Inflammatory Bowel Diseases: Do Immunosuppressive Drugs Matter? AR Bourgonje, AT Otten Clinical Gastroenterology and Hepatology 21 (7), 1971-1972, 2023 | 1 | 2023 |
| Temporary diverting stoma in therapy‐refractory luminal colonic Crohn's disease: an alternative to immediate colorectal resection? AM van Der Holst, AT Otten, EMM Praag, AR van Renterghem, ... Colorectal Disease 25 (6), 1176-1186, 2023 | 1 | 2023 |
| Use of tumor necrosis factor-α antagonists is associated with attenuated IgG antibody response against SARS-CoV-2 in vaccinated patients with inflammatory bowel disease AT Otten, AR Bourgonje, PP Horinga, HH van der Meulen, EAM Festen, ... Frontiers in immunology 13, 920333, 2022 | 1 | 2022 |
| Use of TNF-α-antagonists and systemic steroids is associated with attenuated imunogenicity against SARS-CoV-2 in fully vaccinated patients with Inflammatory Bowel Disease AT Otten, AR Bourgonje, PP Horinga, HH van der Meulen, ... Journal of Crohn's and Colitis 16 (Suppl (1)), S538, 2021 | 1 | 2021 |
| The Future of Therapeutic Drug Monitoring in Inflammatory Bowel Disease: An Emphasis on the Essential Ingredients AT Otten, G Dijkstra, MC Visschedijk, AR Bourgonje Inflammatory Bowel Diseases 30 (2), 318-319, 2024 | | 2024 |
| Tu1760 CLINICAL VALIDATION OF A CAPILLARY BLOOD HOME-SAMPLING TECHNIQUE FOR MONITORING OF INFLIXIMAB AND VEDOLIZUMAB CONCENTRATIONS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE AT Otten, H van der Meulen, M Steenhuis, D Touw, J Kosterink, H Frijlink, ... Gastroenterology 164 (6), S-1113, 2023 | | 2023 |
| Capsules with Ileocolonic-Targeted Release of Vitamin B2, B3, and C (ColoVit) Intended for Optimization of Gut Health: Development and Validation of the … AA Ahmed, AT Otten, B Gareb, JE Huijmans, AC Eissens, A Rehman, ... Pharmaceutics 15 (5), 1354, 2023 | | 2023 |
| Assessment of Fecal Glycosylated Mucins as Novel Biomarkers in Inflammatory Bowel Diseases S Geertsema, AT Otten, DG Bouwknegt, MC Visschedijk, AR Bourgonje Inflammatory Bowel Diseases 29 (3), e10-e11, 2023 | | 2023 |
| Working towards a comprehensive appraisal of vaccine-induced immunity against SARS-CoV-2 in IBD AT Otten, AR Bourgonje, MC Visschedijk The Lancet Gastroenterology & Hepatology 8 (2), 99-100, 2023 | | 2023 |
| Protocol: Effects of ileocolonic delivered vitamin B2, B3 and C (ColoVit) or the Groningen anti-inflammatory diet on disease course and microbiome of patients with Crohn’s … AT Otten, V Peters, I Barth, CL Stevens, AR Bourgonje, HW Frijlink, ... BMJ Open 13 (3), 2023 | | 2023 |
| Towards mucosal application of infliximab in the therapy of enterocolitis (TOMATE): a proof of concept study DJ Buurman, B Gareb, AT Otten, HW Frijlink, JGW Kosterink, G Dijkstra Targeting the ileo-colonic region in inflammatory bowel disease, 169, 2020 | | 2020 |
